News & Insights

VENTEGRA INSIGHTS May 6, 2025

Impact of Various Utilization Management on Per-Member Per-Month Spending for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs)

By Alan K. Fou, PharmD; Mark Shinmoto, PharmD; Elton Teng, PharmD; Jeffrey He, PharmD; Rachel K. Hudson, PharmD, MBA

Rising pharmaceutical costs are a major concern for patients and payors alike and are straining our healthcare system. High demand and high prices in the U.S. for GLP-1 drugs are noticeably contributing to the overall rise in drug spend.

Employing a sustainable management strategy for pharmaceuticals like GLP-1s is necessary to achieve an appropriate balance of clinical and cost considerations.

Ventegra is predicated on the core belief that healthcare in the U.S. should be a societal good, which requires finding a way to maximize the benefits of healthcare while minimizing the financial burden on individuals and society. As a clinically driven organization, we engage our clients, provide them with solid and reliable clinical information, and assist them to make educated clinical and business decisions that work best for them and those they serve. We help develop effective strategies to shift utilization patterns and realize marked decreases in PMPM costs through effective utilization management programs (e.g. step edits, quantity limits, etc.) as well as other benefit design choices.

Recently, our 2024-2025 Managed Care Fellow, Alan Fou, Pharm D and our clinical team presented a closer look at the impact of various UM strategies on per-member per-month spending for GLP-1's.

Download the study poster

Would you like to learn more? Let's connect!

© Ventegra All Rights Reserved. | Policies | Terms of Use